Early Detection and Diagnosis

You have full text access to this OnlineOpen article

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy

  1. Andrew J. Vickers1,2,3,
  2. David Ulmert4,5,
  3. Angel M. Serio1,2,3,
  4. Thomas Björk4,5,
  5. Peter T. Scardino1,2,3,
  6. James A. Eastham1,2,3,
  7. Göran Berglund4,5,
  8. Hans Lilja1,2,3,4,5,†,‡,*

Article first published online: 26 JUL 2007

DOI: 10.1002/ijc.22956

Issue

International Journal of Cancer

International Journal of Cancer

Volume 121, Issue 10, pages 2212–2217, 15 November 2007

Additional Information

How to Cite

Vickers, A. J., Ulmert, D., Serio, A. M., Björk, T., Scardino, P. T., Eastham, J. A., Berglund, G. and Lilja, H. (2007), The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. Int. J. Cancer, 121: 2212–2217. doi: 10.1002/ijc.22956

Author Information

  1. 1

    Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, New York, NY

  2. 2

    Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY

  3. 3

    Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

  4. 4

    Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmö, Sweden

  5. 5

    Department of Clinical Sciences, Lund University, University Hospital UMAS, Malmö, Sweden

  1. †

    Dr. Hans Lilja holds patents for free PSA and hK2 assays.

  2. ‡

    Fax: +1-646-422-2379.

*Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

Publication History

  1. Issue published online: 25 SEP 2007
  2. Article first published online: 26 JUL 2007
  3. Manuscript Accepted: 30 APR 2007
  4. Manuscript Received: 16 JAN 2007

Funded by

  • National Cancer Institute. Grant Number: P50-CA92629
  • Swedish Cancer Society. Grant Number: 3555
  • European Union 6th Framework. Grant Number: LSHC-CT-2004-503011
  • Fundación Federico SA

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (220K)

References

  • 1
    Catalona WJ, Loeb S, Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 2006; 144: 441–3.
  • 2
    Hoffman RM. Viewpoint: limiting prostate cancer screening. Ann Intern Med 2006; 144: 438–40.
  • 3
    Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 1995; 333: 1401–5.
  • 4
    Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA,Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66–70.
  • 5
    Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67: 762–8.
  • 6
    Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386–99; discussion 98–9.
  • 7
    Martin BJ, Cheli CD, Sterling K, Ward M, Pollard S, Lifsey D, Mercante D, Martin L, Rayford W. Prostate specific antigen isoforms and human glandular kallikrein 2—which offers the best screening performance in a predominantly black population? J Urol 2006; 175: 104–7.
  • 8
    Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 1133–47.
  • 9
    Lilja H, Ulmert D, Bjork T, Becker C, Serio A, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G. Long-term prediction of prostate cancer in a large, representative Swedish cohort: prostate kallikreins measured at age 44–50 predict prostate cancer up to 25 years before diagnosis. J Clin Oncol 2007; 25: 431–6.
  • 10
    Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer 2006; 106: 1507–13.
    Direct Link:
  • 11
    Sindhwani P, Wilson CM. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6: 307–12.
  • 12
    Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 2002; 42: 323–8.
  • 13
    Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005; 63: 13–18.
    Direct Link:
  • 14
    Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, Huland E, Huland H, Lilja H. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 2003; 170: 2269–73.
  • 15
    Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 2006; 13: 238–43.
    Direct Link:
  • 16
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. JUrol 2005; 173: 752–6.
  • 17
    Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, Nilsson JA, Stavenow L. Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. J Intern Med 1996; 239: 489–97.
    Direct Link:
  • 18
    Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H, Lindgarde F. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 2000; 247: 19–29.
    Direct Link:
  • 19
    Mostofi FK. Grading of prostatic carcinoma. Cancer Chemother Rep 1975; 59: 111–17.
  • 20
    Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995; 87: 354–60.
  • 21
    Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594–8.
  • 22
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–94.
  • 23
    Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 2005; 174: 872–6.
  • 24
    Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.
  • 25
    Bosch JL, Tilling K, Bohnen AM, Donovan JL. Establishing normal reference ranges for PSA change with age in a population-based study: the Krimpen study. Prostate 2006; 66: 335–43.
    Direct Link:
View Full Article (HTML) Get PDF (220K)